Australian allogeneic cellular medicines company Mesoblast (ASX:MSB) has reported gross revenue of US$13.2 million from the sales of Ryoncil following its launch at the end of March. …
Mesoblast updates investors on the succesful US launch of cell medicine
July 20, 2025 Australian Biotech
Latest Video
New Stories
-
Mesoblast updates investors on the succesful US launch of cell medicine
July 20, 2025 - - Australian Biotech -
Australian researcher awarded Gilead Sciences global grant to explore novel approach in breast cancer
July 18, 2025 - - Latest News -
The 'Dispatched' Week in Review Podcast - 17 July
July 17, 2025 - - Podcast -
Another day, another confusing response to the threat of US tariffs
July 17, 2025 - - Latest News -
NDIS keeps growing but signs emerge that reforms are starting to work
July 17, 2025 - - Latest News -
USTR launches new investigation, with minimal ambition on pharmaceuticals
July 17, 2025 - - Latest News -
New Zealand starting to benefit after lifting advertising prohibition
July 17, 2025 - - Latest News